Recursion Pharmaceuticals, Inc. (RXRX)

3.375 +0.04 (+1.35%) USD  |  NASDAQ  |  Sep 02, 16:00
3.36 -0.02 (-0.44%) After-Hours: 20:00
More

Recursion Pharmaceuticals Cash from Operations (Annual) : -371.81M for Dec. 31, 2025

Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for RXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2019. Start Trial.
Date Value
December 31, 2025 -371.81M
December 31, 2024 -359.17M
December 31, 2023 -287.78M
December 31, 2022 -83.52M
Date Value
December 31, 2021 -158.61M
December 31, 2020 -45.40M
December 31, 2019 -57.04M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Twist Bioscience Corp. -47.63M
Absci Corp. -92.92M
Novavax, Inc. -244.64M
Editas Medicine, Inc. -165.24M
Halozyme Therapeutics, Inc. 651.56M